CORRECTED-Healthcare firm Neuronetics Q2 revenue beats estimates
Overview
Neuronetics Q2 2025 revenue rises 132% yr/yr to $38.1 mln, beating estimates
U.S. clinic revenue from Greenbrook acquisition was $23.0 mln in Q2 2025
Company reduced cash used in operations to $3.5 mln, beating guidance
Outlook
Neuronetics expects Q3 revenue between $37 mln and $39 mln
Company maintains full-year revenue guidance of $149 mln to $155 mln
Neuronetics anticipates full-year gross margin between 48% and 50%
Company expects Q3 cash flow from operations to range from negative $3 mln to break-even
Result Drivers
GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook acquisition, contributing $23.0 mln in U.S. clinic revenue
NEUROSTAR DECLINE - NeuroStar Advanced Therapy System revenue decreased 13% due to strategic focus on higher volume accounts
TREATMENT SESSION PERFORMANCE - Record quarterly performance in treatment session revenue on pro forma basis, despite absence of Greenbrook sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beats | $38.1 mln | $36.80 mln (3 Analysts) |
Q2 Gross Margin |
| 46.6% |
|
Q2 Operating Expenses |
| $25.80 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 33.4% above its August 4 closing price of $4.66
Press Release: ID:nGNX1SvD68
